Table 3.

Observed survival of refractory DLBCL according to approximations of the SCHOLAR-1 (17) definitions.

	At 2 years		At 5 years		Median OS (years)
	Estimate	95% CI	Estimate	95% CI
All refractory DLBCL cases	28.57	[20.5, 37.1]	26.61	[18.8, 35.1]	0.7
Refractory per SCHOLAR-1 def.	.		.
Refractory at first-line	20.00	[11.9, 29.7]	18.67	[10.8, 28.2]	0.6
Refractory at second-line	31.03	[15.6, 47.9]	31.03	[15.6, 47.9]	0.5
Refractory at post-ASCT	47.62	[25.7, 66.7]	42.86	[21.9, 62.3]	1.7

The starting point for each group is different and defined as the start of the first (salvage) therapy after becoming refractory. Refractory at first-line: patients starting any second-line regimen < 12 weeks after the end of ≥ 4 cycles of any first line regimen (n = 75). Refractory at second-line: patients starting a third line regimen < 12 weeks after ≥ 2 cycles of any second-line regimen (n = 29). Refractory at post-ASCT: patients starting any therapy (radiotherapy, chemotherapy, or HSCT) < 12 months after start of ASCT (ASCT within 2 years from incidence) (n = 23). Treatments were only considered during the 2 years of follow-up after for diagnosis.

CI, confidence interval.